title: [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
abstract: BACKGROUND
  In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure.
  
  
  OBJECTIVE
  The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure.
  
  
  METHODS
  Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation.
  
  
  RESULTS
  All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients.
  
  
  CONCLUSIONS
  Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland. michael.autenrieth@tum.de.
authors.forename: M E
authors.initials: ME
authors.lastname: Autenrieth
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: T
authors.initials: T
authors.lastname: Horn
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: F
authors.initials: F
authors.lastname: Kurtz
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Nguyen
authors.affiliation: Institut für Transurane der Europäischen Kommission, Karlsruhe, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Morgenstern
authors.affiliation: Institut für Transurane der Europäischen Kommission, Karlsruhe, Deutschland.
authors.forename: F
authors.initials: F
authors.lastname: Bruchertseifer
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Schwaiger
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Blechert
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Seidl
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: R
authors.initials: R
authors.lastname: Senekowitsch-Schmidtke
authors.affiliation: Klinik und Poliklinik für Urologie, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: J E
authors.initials: JE
authors.lastname: Gschwend
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, TU München, München, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Scheidhauer
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D010865:Pilot Projects; D016499:Radioimmunotherapy / Q000379:methods*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine
keywords: Cystectomy, radical; Instillation, bladder; Radioimmunotherapy; Resection, transurethral; Tumor recurrence